Accelerate and De-Risk Your Path
from Target to Lead
DiscoveryMAXX is Axxam’s fully integrated, target-to-lead early drug discovery program.
Designed to translate complex biology into high-quality leads, DiscoveryMAXX provides a streamlined path from Disease → Target → Molecule, meticulously structured to reduce risk at every stage, enabling seamless progression into clinical development with unmatched confidence and precision.
DiscoveryMAXX is built on the principle that better decisions made early in drug discovery significantly reduce the risk of failure, delays, and budget overruns in preclinical and clinical development. Many drug candidates fail due to inadequate on-target efficacy, off-target safety and toxicity, challenges in biodistribution, issues with manufacturing scalability, or misalignment with Target Product Profile (TPP) expectations. These factors can interrupt program progression and limit opportunities for partnering or successful transactions.
This milestone-driven program accelerates pipelines efficiently and generates high-quality, fit-for-purpose data packages that support progression to the next development stage and strengthen the case for fundraising, financing tranches, or strategic partnerships.
Axxam operates as timeline-focused scientific group who strategizes, adapts, and executes as an extension of your team. We leverage deep expertise in innovative biology, advanced screening technologies, and in vitro pharmacology to support strong decision-making from the outset. Our model brings together scientific depth, stable and experienced teams, and clear accountability at every step.
Why DiscoveryMAXX? De-risking and value creation through science
✔ Reduced scientific and operational risk
AI-enhanced target identification, evaluation, and prioritization, supported by multi-omics data, enable data-informed decision making and early de-risking of drug discovery programs. Clearly defined milestones and stringent QC criteria guide every module. Early in-vitro assessment of efficacy, biodistribution, and toxicity, including the use of NAMs (New Approach Methodologies), flags potential issues sooner and keeps your project on track.
✔ Faster, more informed decisions
DiscoveryMAXX eliminates the typical fragmentation of early discovery by integrating biology, chemistry, informatics, and project governance into one cohesive workflow. All data flow through a unified framework providing full transparency and real-time insight across the entire program.
✔ Access to exclusive chemical space
Screening leverages Axxam’s proprietary compound decks (450.000 physical compounds and 19 million virtual), including universal and focused libraries, novel scaffolds, natural product collections, and fully customizable virtual subsets. This ensures hit diversity, synthetic tractability, and high novelty.
✔ Continuity and seamless collaboration
A dedicated Axxam team follows your project from start to finish, ensuring scientific and operational continuity while working as an extension of your R&D team. DiscoveryMAXX includes clear and routine communication, transparent presentation of data and progress, and proactive problem-solving to support informed decisions at every stage. Flexible entry points allow you to begin from a disease hypothesis, a validated target, or an established assay, ensuring the program adapts to your scientific and strategic needs.
✔ Flexible models and scalable resourcing
Axxam prioritizes transparency and flexibility through adaptable financial models, clear invoicing schedules, real-time project Gantt charts, and resource allocation tailored to complement your internal capabilities. FTE resources can be scaled up or down as needed to match timelines, budgets, and deliverables. Cancellation and termination terms are designed to be accommodating, ensuring that DiscoveryMAXX remains a solution that truly fits your organization.
The DiscoveryMAXX workflow
DiscoveryMAXX brings together AI-enhanced target identification, rigorous wet-lab validation, and robust assay development to ensure that programs start on a strong foundation for all downstream decisions.
High-throughput and high-content screening, integrated with virtual screening, enable the identification of high-value hits with early insights into efficacy, toxicity, and safety. The program includes a focused hit-to-lead engine supported by medicinal chemistry, iterative SAR, and tiered ADME and safety testing to generate potent, selective, and developable leads.
Innovative chemistry capabilities, including diverse screening collections, DNA-encoded libraries, customized virtual libraries, and click chemistry, further expand chemical diversity and discovery potential. Standardized, interoperable data workflows ensure faster, more confident decision-making at every stage of the discovery process.
Why choosing Axxam as an extention of your team?
We are a biology powerhouse translating innovative biology into bioactive molecules. We specialize in target validation, assay development, high-throughput screening, in vitro pharmacology, and hit-to-lead activities.
- Track record: Over the years, Axxam has successfully contributed to the development of more than 500 functional assays and has executed 335 high-throughput screening campaigns, ensuring deep expertise across modalities and target classes.
- We have successfully supported hundreds of discovery programs. Here is a selection of these successes for which Axxam performed all stages from assay development, screening using Axxam’s libraries, and hit-to-lead:
- De -risk operations: Axxam has proudly obtained ISO certifications for quality management, information security management, and occupational health and safety management, as well as an EcoVadis medal in recognition of our commitment to sustainability and corporate responsibility. These achievements underscore our dedication to integrating quality, security, safety, and sustainability into everything we do, because for us, improvement is not an obligation; it is a choice.
Who benefits most from DiscoveryMAXX?
Axxam has delivered on milestones as an innovative partner for:
Biotechs: often entering with their own target or partially developed assays and looking for strategic workflow guidance and support to build robust biology and generate the high-quality data needed for decision making, timely milestones, fundraising, value-inflection points, and transaction-ready assets.
- Pharma teams: seeking external innovation, specialized assay development, scalable screening capabilities, and integrated hit-to-lead expertise to accelerate internal pipelines, expand discovery capacity, and efficiently progress validated targets with reduced operational burden.
- Venture capital and investors: seeking rapid evaluation and prioritization of targets within and across therapeutic areas to de-risk asset concepts, and using Axxam as a complete drug discovery engine for virtual or small portfolio companies.
- Academic groups: bringing forward novel biology, disease insights, or early target concepts that require industrial-grade assay development, screening, and translational expertise to generate valuable data packages that support publications, partnerships, and technology transfer opportunities.
Schedule a quick call to discuss how Axxam can accelerate and de-risk your drug discovery program, providing a clear path and timeline to key milestones and deliverables for both leadership and investors.
Related content
Case study – Axxam for THERAtRAME
Learn more about how Axxam supported THERAtRAME in discovery the first-in-class anti-cancer inhibitors targeting the ELP3-tRNA interface
Case study – Axxam for Libra Therapeutics
Discover more about how Axxam supported Libra Therapeutics in their small molecule TRPML1 agonist journey